Company (Location)

Product

Description

Indication

Status (Date)#

Aeterna Zentaris Inc. (Quebec City)

AEZS-108

Targeted cytotoxic luteinizing hormone-releasing hormone analogue

Castration- and taxane-resistant prostate cancer

Phase I data from a Phase I/II study showed it was safe and demonstrated efficacy even at low doses (9/27)

Algeta ASA (Oslo, Norway)

Alpharadin

Alpha-emitting radiotherapy

Bone metastases in patients with hormone-resistant prostate cancer

Phase III data showed it met the primary endpoint of overall survival, plus seondary endpoints, including a reduction in the number of bone fractures; median survival was 14 months compared to 11.2 months for placebo (9/27)

Boehringer Ingelheim GmbH (Ingelheim, Germany)

BIBF 1120

Orally administered triple angiokinase inhibitor that targets three receptor tyrosine kinases: FGFR, PDGFR and VEGFR

Metastatic colorectal cancer

In combination with mFOLFOX6 it showed median progression-free survival of 10.6 months in a Phase II trial in 126 patients (9/27)

ImmunoGen Inc. (Waltham, Mass.) and Roche AG (Basel, Switzerland)

T-DM1

Trastuzumab emtansine

HER2-positive metastatic breast cancer

Phase II data showed that median progression-free survival was significantly greater for T-DM1-treated patients compared to Herceptin plus chemotherapy (14.2 months vs. 9.2 months) (9/27)

Millennium (Cambridge Mass.) and Seattle Genetics Inc. (Bothell, Wash.)

Adcetris

Antibody drug brentuximab vedotin

Hodgkin lymphoma or systemic anaplastic large-cell lymphoma

A retrospective analysis of pediatric patients enrolled in four trials, two Phase I and two Phase II, showed treatment resulted in a complete remission in six of nine patients, including all four sALCL patients, with the remaining three patients achieving stable disease (9/27)

MolMed SpA (Milan, Italy)

NGR-hTNF

Cancer candidate

Non-small-cell lung cancer, ovarian cancer and small-cell lung cancer

Phase II data showed evidence of improved disease control and greater progression-free survival compared to chemotherapy alone in non-small-cell lung cancer; Phase II data in ovarian and small-cell lung cancer showed long-term clinical benefit (9/28)

Roche AG (Basel, Switzerland)

Avastin

Bevacizumab

Metastatic colorectal cancer

Ocala (Fla.) Oncology said study data showed patients treated in a community setting with bevacizumab beyond progression experienced improved overall survival (9/30)

Synta Pharmaceuticals Corp. (Lexington, Mass.)

Ganetespib

A heat-schock protein 90 inhibitor

Solid tumors

Phase I data showed it was well tolerated when given in combination with docetaxel (9/27)

Notes:

Public biotech company stock symbols can be found in the stock report located on the last two pages of this issue.

# The date indicated refers to the BioWorld Today issue in which the news item can be found.